- In May 2024, Osel Inc., a U.S.-based biotech firm, announced new clinical trial results for LACTIN-V, a live biotherapeutic product containing Lactobacillus crispatus CTV-05. The study demonstrated significant efficacy in preventing the recurrence of bacterial vaginosis (BV) among women previously treated with antibiotics. This milestone strengthens the case for targeted probiotic therapies as viable alternatives to traditional treatments and reinforces Osel's leadership in vaginal microbiome therapeutics
- In March 2024, Symbiome Health, a women’s health startup, launched a direct-to-consumer range of strain-specific vaginal probiotics featuring dual delivery formats (oral capsules and suppositories). The launch targets women experiencing recurrent infections and flora imbalances, with personalized options based on lifestyle and hormonal changes. This expansion highlights the growing trend of personalized, non-prescription intimate care solutions rooted in microbiome science
- In February 2024, Evvy, a health-tech company focused on vaginal microbiome diagnostics, partnered with multiple clinics across North America to integrate microbiome sequencing-based testing with probiotic-based therapeutic recommendations. This collaboration aims to empower clinicians and patients with data-driven decisions in managing vaginal health, underlining the shift toward precision care in this domain
- In January 2024, NovoBiome, a European biotech firm, secured funding for the development of a new generation of oral and intravaginal probiotic formulations aimed at supporting vaginal flora during and after antibiotic use. The initiative focuses on blending Lactobacillus rhamnosus and Bifidobacterium longum strains with prebiotic fibers, emphasizing the growing interest in synbiotic approaches to intimate wellness
- In December 2023, NutraFemme, an Australian nutraceutical company, announced its expansion into Asian markets with its line of hormone-sensitive probiotic products tailored for menopausal and postpartum women. The move taps into rising demand for natural and microbiome-supportive solutions across new demographic segments, reinforcing NutraFemme’s focus on lifecycle-based vaginal care
